Nimbus Therapeutics, Inc.

When Abbas Kazimi became CEO of Nimbus Therapeutics in March 2025, he didn’t need to introduce a sweeping new three-year vision. After 11 years at the company, having witnessed its evolution from a bo

Included for 2025 are investors, CEOs of small and mid-sized companies, rising employees in larger businesses, and individuals spearheading unique health initiatives worldwide. The 30 individuals list

It has been less than three years since Atlas Venture closed its thirteenth venture capital fund and one thing is unchanged with its fourteenth – the size of the fund. Atlas announced on 5 December th

The stats are known by now: 90% of drug candidates fail during the development process. While artificial intelligence (AI) is touted for its potential to reduce the overall failure rate, a more modest